JP Morgan Chase’s CorMedix CRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $515K | Sell |
67,415
-48,545
| -42% | -$384K | ﹤0.01% | 5092 |
|
|
2026
Q1 | $762K | Buy |
115,960
+8,192
| +8% | +$60.6K | ﹤0.01% | 4759 |
|
|
2025
Q4 | $1.25M | Buy |
107,768
+10,540
| +11% | +$117K | ﹤0.01% | 4445 |
|
|
2025
Q3 | $1.13M | Buy |
97,228
+62,085
| +177% | +$751K | ﹤0.01% | 4494 |
|
|
2025
Q2 | $433K | Sell |
35,143
-1,094
| -3% | -$12.1K | ﹤0.01% | 4857 |
|
|
2025
Q1 | $223K | Sell |
36,237
-236,981
| -87% | -$2.45M | ﹤0.01% | 5197 |
|
|
2024
Q4 | $2.21M | Buy |
273,218
+79,110
| +41% | +$790K | ﹤0.01% | 4078 |
|
|
2024
Q3 | $1.57M | Buy |
194,108
+169,397
| +686% | +$917K | ﹤0.01% | 4184 |
|
|
2024
Q2 | $107K | Buy |
24,711
+2,467
| +11% | +$12.5K | ﹤0.01% | 5484 |
|
|
2024
Q1 | $94.3K | Sell |
22,244
-15,481
| -41% | -$53.7K | ﹤0.01% | 5698 |
|
|
2023
Q4 | $142K | Buy |
37,725
+3,156
| +9% | +$10.9K | ﹤0.01% | 5572 |
|
|
2023
Q3 | $128K | Sell |
34,569
-24,109
| -41% | -$95.9K | ﹤0.01% | 5336 |
|
|
2023
Q2 | $233K | Buy |
58,678
+58,483
| +29,991% | +$289K | ﹤0.01% | 4989 |
|
|
2023
Q1 | $1K | Hold |
195
| – | – | ﹤0.01% | 6506 |
|
|
2022
Q4 | $1K | Sell |
195
-21,388
| -99% | -$75.7K | ﹤0.01% | 6388 |
|
|
2022
Q3 | $62K | Sell |
21,583
-57,290
| -73% | -$238K | ﹤0.01% | 5470 |
|
|
2022
Q2 | $317K | Buy |
78,873
+38,431
| +95% | +$143K | ﹤0.01% | 4824 |
|
|
2022
Q1 | $221K | Buy |
40,442
+1,968
| +5% | +$9.01K | ﹤0.01% | 5136 |
|
|
2021
Q4 | $175K | Buy |
38,474
+11,390
| +42% | +$56.5K | ﹤0.01% | 5426 |
|
|
2021
Q3 | $126K | Sell |
27,084
-23,359
| -46% | -$136K | ﹤0.01% | 5454 |
|
|
2021
Q2 | $346K | Sell |
50,443
-7,903
| -14% | -$62.9K | ﹤0.01% | 4929 |
|
|
2021
Q1 | $583K | Sell |
58,346
-27,373
| -32% | -$288K | ﹤0.01% | 4583 |
|
|
2020
Q4 | $636K | Buy |
85,719
+56,897
| +197% | +$387K | ﹤0.01% | 4235 |
|
|
2020
Q3 | $170K | Buy |
28,822
+14,858
| +106% | +$74.6K | ﹤0.01% | 4434 |
|
|
2020
Q2 | $88K | Buy |
13,964
+5,799
| +71% | +$26.8K | ﹤0.01% | 4619 |
|
|
2020
Q1 | $29K | Sell |
8,165
-18,711
| -70% | -$106K | ﹤0.01% | 4868 |
|
|
2019
Q4 | $195K | Buy |
26,876
+19,150
| +248% | +$117K | ﹤0.01% | 4677 |
|
|
2019
Q3 | $49K | Buy |
7,726
+1,253
| +19% | +$10.5K | ﹤0.01% | 5183 |
|
|
2019
Q2 | $49K | Buy |
+6,473
| New | +$50.8K | ﹤0.01% | 5174 |
|
|
2016
Q3 | – | Sell |
-2,941
| Closed | -$29K | – | 4582 |
|
|
2016
Q2 | $29K | Buy |
+2,941
| New | +$44.8K | ﹤0.01% | 4158 |
|
Other funds holding CRMD
DTC
RA
OAM
JP Morgan Chase's CRMD Position: Q2 2026 in Review
JP Morgan Chase reduced its CorMedix (CRMD) stake by 42% in Q2 2026, selling an estimated $384K and leaving 67,415 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #5092.
JP Morgan Chase first reported a position in CRMD in Q2 2016 and has held it in 30 quarters since. The position peaked at $2.21M in Q4 2024. 189 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.
- JP Morgan Chase held 67,415 shares of CorMedix worth $515K as of Q2 2026.
- JP Morgan Chase sold 48,545 CorMedix shares in Q2 2026, an estimated $384K.
- CorMedix made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5092 holding.
- JP Morgan Chase first reported a position in CorMedix in Q2 2016 and has held it in 30 quarters since.
- JP Morgan Chase's CorMedix position peaked at $2.21M in Q4 2024.
- 189 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.